MADISON, Wis., Aug. 13, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the fourth quarter and fiscal 2025, ended June 30, 2025.
Key Fiscal Fourth Quarter Highlights
Key Fiscal Year 2025 Highlights
"We continued to advance our strategy of innovation, access and service growth within the quarter and I am proud of how we navigated a challenging environment both within the quarter and for the fiscal year," said Suzanne Winter, President and Chief Executive Officer. "In addition to annual revenue growth, strong service performance and adjusted EBITDA margin expansion, we successfully completed a refinancing of our debt with a strong partner that is invested in our long-term success."
Fiscal Fourth Quarter Results
Total net revenue was $127.5 million for the fourth quarter of fiscal 2025, or a decrease of 5 percent, as compared to $134.3 million in the prior fiscal year fourth quarter. Product revenue totaled $70.7 million, or a decrease of 11 percent, as compared to $79.7 million in the prior fiscal year fourth quarter, while service revenue totaled $56.8 million, or an increase of 4 percent, as compared to $54.6 million in the prior fiscal year fourth quarter.
Total gross profit in the fourth quarter of fiscal 2025 was $39.0 million, or 30.6 percent of net revenue, as compared to total gross profit of $38.5 million, or 28.6 percent of net revenue in the prior fiscal year fourth quarter.
Operating expenses were $34.7 million in the fourth quarter of fiscal 2025, or an increase of 10 percent, as compared to $31.6 million in the prior fiscal year fourth quarter.
Net income was $1.1 million, or $0.01 per share, in the fourth quarter of fiscal 2025, as compared to a net income of $3.4 million, or $0.03 per share, in the prior fiscal year fourth quarter. Adjusted EBITDA was $9.4 million in the fourth quarter of fiscal 2025 compared to $10.1 million in the prior fiscal year fourth quarter.
Ending order backlog as of June 30, 2025 was $427.0 million, 5.6 percent lower from the third quarter of fiscal 2025, and 12.4 percent lower than at the end of the prior fiscal year fourth quarter.
Cash, cash equivalents, and short-term restricted cash were $58.0 million as of June 30, 2025, a decrease of $20.8 million from March 31, 2025.
Fiscal Year 2025 Highlights
Total net revenue was $458.5 million for fiscal 2025, or an increase of 3 percent, as compared to $446.6 million in the prior fiscal year period. Product revenue totaled $237.6 million, or an increase of 1 percent, as compared to $234.2 million in the prior fiscal year period. Service revenue totaled $220.9 million, or an increase of 4 percent, as compared to $212.4 million in the prior fiscal year period.
Total gross profit was $147.0 million for fiscal 2025, or 32.1 percent of net revenue, as compared to total gross profit of $142.9 million, or 32.0 percent of net revenue in the prior fiscal year period.
Operating expenses were $139.1 million for fiscal 2025, or a decrease of 2 percent, as compared to $142.4 million for the prior fiscal year period.
GAAP net loss was $1.6 million, or $0.02 per share, for the fiscal 2025, as compared to a net loss of $15.5 million, or $0.16 per share, in the prior fiscal year period. Adjusted EBITDA was $28.3 million for fiscal 2025, as compared to $19.7 million in the prior fiscal year period.
"Our fourth quarter and full year financial results demonstrate the resilience of our team despite macroeconomic challenges and continuing tariff uncertainty. We made steady operational progress while continuing to drive customer adoption through the expansion of our product portfolio. We also announced refinancing plans with a partner committed to advancing our global business. I look forward to working with them, together with the global Accuray team, to execute on our core strategies for driving consistent growth," said Ali Pervaiz, Chief Financial Officer at Accuray.
Fiscal Year 2026 Financial Guidance
Accuray's financial guidance is based on current expectations. The following statements are forward-looking and actual results could differ materially depending on market and economic conditions, supply chain disruption, and the factors set forth under "Safe Harbor Statement" below.
The Company is introducing guidance for fiscal year 2026 as follows:
Guidance for Adjusted EBITDA, a non-GAAP financial measure excludes depreciation and amortization, stock-based compensation expense, interest expense and provision for income taxes. For more information regarding the non-GAAP financial measures discussed in this press release, please see "Use of Non-GAAP Financial Measures" below.
Conference Call Information
Accuray will host a conference call beginning at 1:30 p.m. PT/4:30 p.m. ET today to discuss results for the fourth quarter of fiscal 2025 as well as recent corporate developments. Conference call dial-in information is as follows:
Individuals interested in listening to the live conference call via the Internet may do so by logging on to the Investor Relations section of Accuray's website, www.accuray.com. There will be a slide presentation accompanying today's event which can also be accessed on the company's Investor Relations page at www.accuray.com.
In addition, a taped replay of the conference call will be available beginning approximately one hour after the call's conclusion and will be available for seven days. The replay number is (877) 344-7529 (USA), or (412) 317-0088 (International), Conference ID: 3326908. An archived webcast will also be available on Accuray's website until Accuray announces its results for the first quarter of fiscal 2026.
Use of Non-GAAP Financial Measures
Accuray reports its financial results in accordance with generally accepted accounting principles in the United States ("GAAP") and the rules of the SEC. To supplement its financial statements prepared and presented in accordance with GAAP, Accuray uses certain non-GAAP financial measures, such as adjusted EBITDA.
Accuray has supplemented its GAAP net income (loss) with a non-GAAP measure of adjusted earnings before interest, taxes, depreciation, amortization, stock-based compensation, changes to the fair value of warrant liability, ERP and ERP related expenditures and restructuring charges ("adjusted EBITDA"). The calculation of adjusted EBITDA also excludes certain non-recurring, irregular and one-time items. Management believes that this non-GAAP financial measure provides useful supplemental information to management and investors regarding the performance of the company and facilitates a meaningful comparison of results for current periods with previous operating results. A reconciliation of GAAP net income (loss) (the most directly comparable GAAP measure) to non-GAAP adjusted EBITDA is provided in the schedules below.
There are limitations in using these non-GAAP financial measures because they are not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial measures. Investors and potential investors should consider non-GAAP financial measures only in conjunction with the company's consolidated financial statements prepared in accordance with GAAP.
About Accuray
Accuray Incorporated (Nasdaq: ARAY) is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions that are designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Madison, Wisconsin, with facilities worldwide.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to the company's guidance and future results of operations, including expectations regarding: total net revenue and adjusted EBITDA; the company's ability to deliver sustained performance and execute on its strategies; expectations regarding the impact of tariffs as well as mitigation efforts by the company; expectations regarding the company's refinancing and refinancing partner; the company's ability to navigate supply chain, logistics, macroeconomic, and foreign exchange challenges; the company's ability to achieve its longer-term goals; expectations regarding the company's China joint venture; expectations related to the amount and timing of realizing deferred margin from the company's China joint venture; expectations with respect to strategic partnerships and collaborations; expectations related to the markets and regions in which the company operates; expectations regarding new product introductions and innovations; expectations regarding service business growth and its ability to serve as a growth driver; expectations regarding installed base growth; and the company's ability to advance patient care and offer value to its customer. These forward-looking statements involve risks and uncertainties. If any of these risk or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results express or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the effect of the global macroeconomic environment on the operations of the company and those of its customers and suppliers; disruptions to our supply chain, including increased logistics costs; the company's ability to achieve widespread market acceptance of its products; substantial outstanding indebtedness and its ability to maintain compliance with financial covenants related to its debt; the effect of enhanced international tariffs on the company; the company's ability to realize the expected benefits of the China joint venture and other partnerships; risks inherent in international operations; the company's ability to maintain or increase its gross margins on product sales and services; delays in regulatory approvals or the development or release of new offerings; the company's ability to meet the covenants under its credit facilities; the company's ability to convert backlog to revenue; and such other risks identified under the heading "Risk Factors" in the company's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (the "SEC") on May 2, 2025, and as updated periodically with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
Aman Patel, CFA | Beth Kaplan |
Investor Relations, ICR-Westwicke | Public Relations Director, Accuray |
+1 (443) 450-4191 | +1 (408) 789-4426 |
This email address is being protected from spambots. You need JavaScript enabled to view it. | This email address is being protected from spambots. You need JavaScript enabled to view it. |
Financial Tables to Follow
Accuray Incorporated | ||||||||||||||||
Three Months Ended | Twelve Months Ended | |||||||||||||||
2025 | 2024 | 2025 | 2024 | |||||||||||||
Net revenue: | ||||||||||||||||
Products | $ | 70,702 | $ | 79,673 | $ | 237,580 | $ | 234,164 | ||||||||
Services | 56,841 | 54,616 | 220,925 | 212,387 | ||||||||||||
Total net revenue | 127,543 | 134,289 | 458,505 | 446,551 | ||||||||||||
Cost of revenue: | ||||||||||||||||
Cost of products | 51,254 | 55,084 | 162,569 | 161,061 | ||||||||||||
Cost of services | 37,310 | 40,753 | 148,969 | 142,569 | ||||||||||||
Total cost of revenue | 88,564 | 95,837 | 311,538 | 303,630 | ||||||||||||
Gross profit | 38,979 | 38,452 | 146,967 | 142,921 | ||||||||||||
Operating expenses: | ||||||||||||||||
Research and development | 11,470 | 9,529 | 47,942 | 49,732 | ||||||||||||
Selling and marketing | 11,409 | 10,696 | 43,315 | 42,619 | ||||||||||||
General and administrative | 11,866 | 11,410 | 47,871 | 50,066 | ||||||||||||
Total operating expenses | 34,745 | 31,635 | 139,128 | 142,417 | ||||||||||||
Income from operations | 4,234 | 6,817 | 7,839 | 504 | ||||||||||||
Income from equity method investment | 885 | 810 | 4,714 | 1,838 | ||||||||||||
Interest expense | (4,226) | (2,895) | (12,954) | (11,624) | ||||||||||||
Gain on extinguishment of debt | 1,475 | — | 1,475 | — | ||||||||||||
Loss from change in fair value of warrant liability | (499) | — | (499) | — | ||||||||||||
Other income (expense), net | 202 | (874) | 559 | (2,538) | ||||||||||||
Income (loss) before provision for income taxes | 2,071 | 3,858 | 1,134 | (11,820) | ||||||||||||
Provision for income taxes | 948 | 471 | 2,725 | 3,725 | ||||||||||||
Net income (loss) | $ | 1,123 | $ | 3,387 | $ | (1,591) | $ | (15,545) | ||||||||
Net income (loss) per share - basic | $ | 0.01 | $ | 0.03 | $ | (0.02) | $ | (0.16) | ||||||||
Net income (loss) per share - diluted | $ | 0.01 | $ | 0.03 | $ | (0.02) | $ | (0.16) | ||||||||
Weighted average common shares used in computing income | ||||||||||||||||
Basic | 106,702 | 99,585 | 102,768 | 98,272 | ||||||||||||
Diluted | 108,891 | 101,028 | 102,768 | 98,272 | ||||||||||||
Accuray Incorporated | ||||||||
June 30, | June 30, | |||||||
2025 | 2024 | |||||||
Assets | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 57,416 | $ | 68,570 | ||||
Restricted cash | 574 | 485 | ||||||
Accounts receivable, net | 83,192 | 92,001 | ||||||
Inventories | 141,020 | 138,324 | ||||||
Prepaid expenses and other current assets | 33,501 | 23,006 | ||||||
Deferred cost of revenue | 1,762 | 850 | ||||||
Total current assets | 317,465 | 323,236 | ||||||
Noncurrent assets: | ||||||||
Property and equipment, net | 28,658 | 24,774 | ||||||
Investment in joint venture | 4,612 | 9,826 | ||||||
Operating lease right-of-use assets | 33,115 | 33,773 | ||||||
Goodwill | 57,802 | 57,672 | ||||||
Restricted cash | 4,144 | 1,337 | ||||||
Other assets | 24,443 | 18,009 | ||||||
Total assets | $ | 470,239 | $ | 468,627 | ||||
Liabilities and stockholders' equity | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 34,033 | $ | 50,020 | ||||
Accrued compensation | 14,573 | 17,128 | ||||||
Operating lease liabilities, current | 7,375 | 6,218 | ||||||
Other accrued liabilities | 29,361 | 28,508 | ||||||
Customer advances | 12,197 | 13,988 | ||||||
Deferred revenue | 82,306 | 71,649 | ||||||
Short-term debt, net of unamortized financing costs | 15,583 | 7,756 | ||||||
Total current liabilities | 195,428 | 195,267 | ||||||
Noncurrent liabilities | ||||||||
Operating lease liabilities, non-current | 32,482 | 32,373 | ||||||
Long-term other liabilities | 5,160 | 7,389 | ||||||
Warrant liability | 8,497 | - | ||||||
Deferred revenue | 26,566 | 24,114 | ||||||
Long-term debt, net of unamortized financing costs | 120,937 | 164,400 | ||||||
Total liabilities | 389,070 | 423,543 | ||||||
Stockholders' Equity: | ||||||||
Common stock | 113 | 100 | ||||||
Additional paid-in capital | 602,165 | 566,887 | ||||||
Accumulated other comprehensive loss | (1,837) | (4,222) | ||||||
Accumulated deficit | (519,272) | (517,681) | ||||||
Total stockholders' equity | 81,169 | 45,084 | ||||||
Total liabilities and stockholders' equity | $ | 470,239 | $ | 468,627 | ||||
Accuray Incorporated | ||||||||||||||||
Three Months Ended | Twelve Months Ended | |||||||||||||||
2025 | 2024 | 2025 | 2024 | |||||||||||||
Gross orders | $ | 84,741 | $ | 95,472 | $ | 288,035 | $ | 342,148 | ||||||||
Net orders | 45,282 | 63,773 | 177,233 | 210,914 | ||||||||||||
Order backlog | 426,972 | 487,319 | 426,972 | 487,319 | ||||||||||||
Book to bill ratio (a) | 1.2 | 1.2 | 1.2 | 1.5 | ||||||||||||
(a) Book to bill ratio is defined as gross orders for the period divided by product revenue for the period |
Accuray Incorporated | ||||||||||||||||
Three Months Ended | Twelve Months Ended | |||||||||||||||
2025 | 2024 | 2025 | 2024 | |||||||||||||
GAAP net income (loss) | $ | 1,123 | $ | 3,387 | $ | (1,591) | $ | (15,545) | ||||||||
Depreciation and amortization (a) | 1,598 | 1,507 | 6,150 | 5,905 | ||||||||||||
Stock-based compensation | 2,818 | 2,042 | 10,201 | 9,483 | ||||||||||||
Interest expense, net (b) | 3,937 | 2,686 | 11,762 | 10,676 | ||||||||||||
Gain on extinguishment of debt | (1,475) | — | (1,475) | — | ||||||||||||
Provision for income taxes | 948 | 471 | 2,725 | 3,725 | ||||||||||||
Loss from change in fair value of warrant liability | 499 | — | 499 | — | ||||||||||||
Restructuring charges | — | — | — | 2,633 | ||||||||||||
ERP and ERP related expenditures | — | — | — | 2,815 | ||||||||||||
Adjusted EBITDA | $ | 9,448 | $ | 10,093 | $ | 28,271 | $ | 19,692 | ||||||||
(a) Consists of depreciation, primarily on property and equipment, as well as amortization of intangibles. |
(b) Consists primarily of interest expense associated with outstanding debt. |
Accuray Incorporated | ||||||||
Twelve Months Ending | ||||||||
From | To | |||||||
GAAP net loss | $ | (12,000) | $ | (8,000) | ||||
Depreciation and amortization (a) | 6,000 | 6,000 | ||||||
Stock-based compensation | 10,500 | 10,500 | ||||||
Interest expense, net (b) | 23,500 | 23,500 | ||||||
Provision for income taxes | 3,000 | 3,000 | ||||||
Adjusted EBITDA | $ | 31,000 | $ | 35,000 | ||||
(a) Consists of depreciation, primarily on property and equipment as well, as amortization of intangibles. |
(b) Consists primarily of interest expense associated with outstanding debt. |
| Last Trade: | US$1.49 |
| Daily Change: | 0.01 0.68 |
| Daily Volume: | 1,193,919 |
| Market Cap: | US$153.480M |
May 05, 2025 April 30, 2025 February 05, 2025 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
